Lifileucel tumor-infiltrating lymphocyte cell therapy in patients with unresectable or metastatic mucosal melanoma after disease progression on immune checkpoint inhibitors

Harriet Kluger; Götz Ulrich Grigoleit; Sajeve Thomas; Evidio Domingo-Musibay; Jason A Chesney; Miguel F Sanmamed; Theresa Medina; Mirjana Ziemer; Eric Whitman; Friedrich Graf Finckenstein; Brian Gastman; Jeffrey Chou; Xiao Wu; Giri Sulur; Rana Fiaz; Rongsu Qi; Amod A Sarnaik

doi:10.1002/cac2.70050

Cancer Communications ›› 2025, Vol. 45 ›› Issue (10) : 1229 -1234. DOI: 10.1002/cac2.70050

LETTER TO THE JOURNAL

Lifileucel tumor-infiltrating lymphocyte cell therapy in patients with unresectable or metastatic mucosal melanoma after disease progression on immune checkpoint inhibitors

Author information +

¹. Yale Cancer Center, New Haven, Connecticut, USA

². Helios Klinikum Duisburg, Duisburg, Germany

³. AdventHealth Cancer Institute, Orlando, Florida, USA

⁴. Division of Hematology, Oncology, and Transplantation, Masonic Cancer Center, Minneapolis, Minnesota, USA

⁵. Division of Medical Oncology and Hematology, Brown Cancer Center, Louisville, Kentucky, USA

⁶. University of Navarra Clinic, Pamplona, Navarra, Spain

⁷. Medical Oncology, University of Colorado Cancer Center, Aurora, Colorado, USA

⁸. University Hospital Leipzig, Leipzig, Germany

⁹. Atlantic Melanoma Center, Atlantic Health System, Morristown, New Jersey, USA

¹⁰. Iovance Biotherapeutics, Inc., San Carlos, California, USA

¹¹. Cutaneous Oncology and Immunology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA

Amod.Sarnaik@moffitt.org

Show less

History +

PDF

Cite this article

Download citation ▾

Harriet Kluger, Götz Ulrich Grigoleit, Sajeve Thomas, Evidio Domingo-Musibay, Jason A Chesney, Miguel F Sanmamed, Theresa Medina, Mirjana Ziemer, Eric Whitman, Friedrich Graf Finckenstein, Brian Gastman, Jeffrey Chou, Xiao Wu, Giri Sulur, Rana Fiaz, Rongsu Qi, Amod A Sarnaik. Lifileucel tumor-infiltrating lymphocyte cell therapy in patients with unresectable or metastatic mucosal melanoma after disease progression on immune checkpoint inhibitors. Cancer Communications, 2025, 45(10): 1229-1234 DOI:10.1002/cac2.70050

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Santeufemia DA, Palmieri G, Miolo G, Colombino M, Doro MG, Frogheri L, et al. Current trends in mucosal melanomas: An overview. Cancers (Basel). 2023; 15(5): 1356.

[2]	Clavero-Rovira L, Gómez-Tomás Á, Bassas-Freixas P, Bodet D, Ferrer B, Hernández-Losa J, et al. Mucosal melanoma clinical management and prognostic implications: A retrospective cohort study. Cancers (Basel). 2024; 16(1): 227.

[3]	Newell F, Kong Y, Wilmott JS, Johansson PA, Ferguson PM, Cui C, et al. Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. Nat Commun. 2019; 10(1): 3163.

[4]	Hamid O, Robert C, Ribas A, Hodi FS, Walpole E, Daud A, et al. Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. Br J Cancer. 2018; 119(6): 670–674.

[5]	Teterycz P, Czarnecka AM, Indini A, Spałek MJ, Labianca A, Rogala P, et al. Multimodal treatment of advanced mucosal melanoma in the era of modern immunotherapy. Cancers (Basel). 2020; 12(11): 3131.

[6]

Nakamura Y, Namikawa K, Yoshikawa S, Kiniwa Y, Maekawa T, Yamasaki O, et al. Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study). ESMO Open. 2021; 6(6): 100325.

[7]

Chesney J, Lewis KD, Kluger H, Hamid O, Whitman E, Thomas S, et al. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. J Immunother Cancer. 2022; 10(12): e005755.

[8]	Long GV, Stephen Hodi F, Lipson EJ, Schadendorf D, Ascierto PA, Matamala L, et al. Overall survival and response with nivolumab and relatlimab in advanced melanoma. NEJM Evidence. 2023; 2(4): EVIDoa2200239.

[9]	Goldinger SM, Buder-Bakhaya K, Lo SN, Forschner A, McKean M, Zimmer L, et al. Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. Eur J Cancer. 2022; 162: 22–33.

[10]	Kaunitz GJ, Cottrell TR, Lilo M, Muthappan V, Esandrio J, Berry S, et al. Melanoma subtypes demonstrate distinct PD-L1 expression profiles. Lab Invest. 2017; 97(9): 1063–1071.